PROPEL Data Support Medtronic's Resolute Integrity DES

April 8, 2016—Medtronic announced that 1-year data from the PROPEL study of the company’s Resolute Integrity drug-eluting stent (DES) were unveiled at ACC.16, the American College of Cardiology’s 65th Annual Scientific Session held April 2-4 in Chicago, Illinois. The PROPEL findings demonstrate superior clinical outcomes in real-world challenging cases when compared to the Xience V DES (Abbott Vascular). The study is being conducted by Masato Nakamura, MD, et al.

According to Medtronic, the multicenter PROPEL study followed 800 patients treated with the Resolute Integrity out to 12 months, and compared clinical outcomes with 1,142 patients treated with Xience V from the RESOLUTE All Comers clinical trial. Additionally, 59.3% of Resolute Integrity DES patients were considered complex  (41.7% diabetes patients, 25.7% bifurcations) and 44.7% had small vessels (reference vessel diameter, < 2.5 mm).

The primary endpoint of target lesion failure at 1 year was significantly lower with the Resolute Integrity DES compared with the Xience V DES (4.3% vs 8.5%; P ≤ .001). The Resolute Integrity DES also showed low clinical event rates for secondary endpoints of target vessel myocardial infarction (0.1%) and Academic Research Consortium definite/probable stent thrombosis (0.3%). The Resolute Integrity stent platform, with continuous sinusoid technology, provided excellent deliverability and conformability with 99.1% procedural success, reported Medtronic.